Major depressive disorder (MDD) affects approximately 280 million people globally and is one of the leading causes of ...

Treatment with esketamine combined with an SNRI is linked to fewer adverse outcomes than treatment with an SSRI alone.

Esketamine Market: Revolutionizing Treatment-Resistant Depression The esketamine market is experiencing significant growth, driven by the urgent need for effective treatments for treatment ...

Discover how the brain's most abundant neurotransmitter, glutamate, is revolutionizing psychiatry and offering new hope for ...

As we honor Counseling Awareness Month, Relief Mental Health recognizes the critical role that therapy plays in helping ...

In terms of the newest collaboration, the health care professionals said they decided that having all the services under one roof would be ideal.

However, Medicare may cover the drug Spravato, which contains esketamine. This is an FDA-approved drug that derives from ketamine and may help treatment-resistant depression. Although the FDA has ...

Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...